For example, circulating IGFBP1 and IGFBP2 appear to be involved in regulating acute bioavailability of IGFs, and when their expression is inhibited, they may increase the mitogenic activity, thereby increasing the risk of cancer [80]. This evidence concerns the gene IGFBP2 and cancer.